Progress, prospects, and problems in Epstein-Barr virus vaccine development
- 1 June 2014
- journal article
- review article
- Published by Elsevier in Current Opinion in Virology
- Vol. 6, 1-5
Abstract
No abstract availableKeywords
Funding Information
- University of Minnesota International Center for Antiviral Research and Epidemiology
- University of Minnesota Foundation
- National Institutes of Health (2PO1 DK 13083)
This publication has 30 references indexed in Scilit:
- Increased CD8+ T Cell Response to Epstein-Barr Virus Lytic Antigens in the Active Phase of Multiple SclerosisPLOS Pathogens, 2013
- Behavioral, Virologic, and Immunologic Factors Associated With Acquisition and Severity of Primary Epstein–Barr Virus Infection in University StudentsThe Journal of Infectious Diseases, 2012
- Epstein-Barr Virus: An Important Vaccine Target for Cancer PreventionScience Translational Medicine, 2011
- Soluble Rhesus Lymphocryptovirus gp350 Protects against Infection and Reduces Viral Loads in Animals that Become Infected with Virus after ChallengePLOS Pathogens, 2011
- Anti-Epstein–Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnelMultiple Sclerosis Journal, 2011
- An Updated Meta-Analysis of Risk of Multiple Sclerosis following Infectious MononucleosisPLOS ONE, 2010
- HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphomaProceedings of the National Academy of Sciences, 2010
- Human antibody titers to Epstein–Barr Virus (EBV) gp350 correlate with neutralization of infectivity better than antibody titers to EBV gp42 using a rapid flow cytometry-based EBV neutralization assayVirology, 2009
- Phase I Trial of a CD8+T-Cell Peptide Epitope-Based Vaccine for Infectious MononucleosisJournal of Virology, 2008
- Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young AdultsThe Journal of Infectious Diseases, 2007